Self-Amplifying mRNA Vaccines

Advances in Genetics

Volumn 89, Issue , 2015, Pages 179-233

  Brito, Luis A ^a   Kommareddy, Sushma ^a   Maione, Domenico ^b   Uematsu, Yasushi ^b   Giovani, Cinzia ^b   Berlanda Scorza, Francesco ^d   Otten, Gillis R ^a   Yu, Dong ^a   Mandl, Christian W ^a   Mason, Peter W ^c   Dormitzer, Philip R ^a   Ulmer, Jeffrey B ^a   Geall, Andrew J ^a  

^a Novartis Vaccines Inc   (United States)

^b NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

^c REGENERON PHARMACEUTICALS INC   (United States)

^d Novartis Vaccines Inc   (United States)

Author keywords

Cationic nanoemulsion; Lipid nanoparticle; MRNA vaccine; Nonviral delivery; Nucleic acid vaccine; Self amplifying mRNA vaccine

Indexed keywords

ANTIGEN; MESSENGER RNA; NANOPARTICLE; VACCINE; VIRUS VACCINE;

ANIMAL; CHEMISTRY; ELECTROPORATION; GENETICS; HUMAN;

ANIMALS; ANTIGENS; ELECTROPORATION; HUMANS; NANOPARTICLES; RNA, MESSENGER; VACCINES; VIRAL VACCINES;

EID: 84921498605     PISSN: 00652660     EISSN: None     Source Type: Book Series    
DOI: 10.1016/bs.adgen.2014.10.005     Document Type: Article

References (207)

1. Aberle J.H., Aberle S.W., Kofler R.M., Mandl C.W. Humoral and cellular immune response to RNA immunization with flavivirus replicons derived from tick-borne encephalitis virus. Journal of Virology 2005, 79(24):15107-15113.
2. Allison A.G., Gregoriadis G. Liposomes as immunological adjuvants. Nature 1974, 252(5480):252.
3. Ambegia E., Ansell S., Cullis P., Heyes J., Palmer L., MacLachlan I. Stabilized plasmid-lipid particles containing PEG-diacylglycerols exhibit extended circulation lifetimes and tumor selective gene expression. Biochimica et Biophysica Acta 2005, 1669(2):155-163.
4. Arvin A.M., Fast P., Myers M., Plotkin S., Rabinovich R. Vaccine development to prevent cytomegalovirus disease: report from the National Vaccine Advisory Committee. Clinical Infectious Diseases 2004, 39(2):233-239.
5. Atkins G.J., Fleeton M.N., Sheahan B.J. Therapeutic and prophylactic applications of alphavirus vectors. Expert Reviews in Molecular Medicine 2008, 10:e33.
6. Baca-Estrada M.E., Foldvari M., Snider M., van Drunen Littel-van den Hurk S., Babiuk L.A. Effect of IL-4 and IL-12 liposomal formulations on the inductionof immune response to bovine herpesvirus type-1 glycoprotein D. Vaccine 1997, 15(16):1753-1760.
7. Bagarazzi M.L., Yan J., Morrow M.P., Shen X., Parker R.L., Lee J.C., et al. Immunotherapy against HPV16/18 generates potent TH1 and cytotoxic cellular immune responses. Science Translational Medicine 2012, 4(155). 155ra138.
8. Barrett L.W., Fletcher S., Wilton S.D. Regulation of eukaryotic gene expression by the untranslated gene regions and other non-coding elements. Cellular and Molecular Life Sciences 2012, 69(21):3613-3634.
9. Bernstein D.I., Reap E.A., Katen K., Watson A., Smith K., Norberg P., et al. Randomized, double-blind, Phase 1 trial of an alphavirus replicon vaccine for cytomegalovirus in CMV seronegative adult volunteers. Vaccine 2009, 28(2):484-493.
10. Bettinger T., Carlisle R.C., Read M.L., Ogris M., Seymour L.W. Peptide-mediated RNA delivery: a novel approach for enhanced transfection of primary and post-mitotic cells. Nucleic Acids Research 2001, 29(18):3882-3891.
11. Bogers W.M., Oostermeijer H., Mooij P., Koopman G., Verschoor E.J., Davis D., et al. Potent Immune Responses in Rhesus Macaques Induced by Nonviral Delivery of aSelf-amplifying RNA Vaccine Expressing HIV Type 1 Envelope With a Cationic Nanoemulsion. Journal of Infetiuos Diseases 2014, Advanced online access published October 17.
12. Brazzoli M., Helenius A., Foung S.K., Houghton M., Abrignani S., Merola M. Folding and dimerization of hepatitis C virus E1 and E2 glycoproteins in stably transfected CHO cells. Virology 2005, 332(1):438-453.
13. Breckenridge N.C., Davis R.H. Optimization of repeated-batch transcription for RNA production. Biotechnology and Bioengineering 2000, 69(6):679-687.
14. Bredenbeek P.J., Frolov I., Rice C.M., Schlesinger S. Sindbis virus expression vectors: packaging of RNA replicons by using defective helper RNAs. Journal of Virology 1993, 67(11):6439-6446.
15. Brito L., Chan M., Shaw C., Hekele A., Carsillo T., Schafer M., et al. A cationic nanoemulsion for the delivery of next generation RNA vaccines. Molecular Therapy 2014, accepted article preview 16 July 2014. Advanced online access published August 19.
16. Brown D.T., Hernandez R. Infection of cells by alphaviruses. Advances in Experimental Medicine and Biology 2012, 726:181-199.
17. Brown D.M., Magrath D.I., Neilson A.H., Todd A.R. Hydrolysis of Esters of Monoribonucleotides. Nature 1956, 177(4520):1124-1125.
18. Burrows C.J., Muller J.G. Oxidative nucleobase modifications leading to strand scission. Chemical Reviews 1998, 98(3):1109-1152.
19. Cai Y., Rodriguez S., Hebel H. DNA vaccine manufacture: scale and quality. Expert Review of Vaccines 2009, 8(9):1277-1291.
20. Calabro S., Tortoli M., Baudner B.C., Pacitto A., Cortese M., O'Hagan D.T., et al. Vaccine adjuvants alum and MF59 induce rapid recruitment of neutrophils and monocytes that participate in antigen transport to draining lymph nodes. Vaccine 2011, 29(9):1812-1823.
21. Calabro S., Tritto E., Pezzotti A., Taccone M., Muzzi A., Bertholet S., et al. The adjuvant effect of MF59 is due to the oil-in-water emulsion formulation, none of the individual components induce a comparable adjuvant effect. Vaccine 2013, 31(33):3363-3369.
22. Chatterjee S., Pal J.K. Role of 5'- and 3'-untranslated regions of mRNAs in human diseases. Biology of the Cell 2009, 101(5):251-262.
23. Chee M.S., Bankier A.T., Beck S., Bohni R., Brown C.M., Cerny R., et al. Analysis of the protein-coding content of the sequence of human cytomegalovirus strain AD169. Current Topics in Microbiology and Immunology 1990, 154:125-169.
24. Cooper S., Erickson A.L., Adams E.J., Kansopon J., Weiner A.J., Chien D.Y., et al. Analysis of a successful immune response against hepatitis C virus. Immunity 1999, 10(4):439-449.
25. Cornelius M.G., Schmeiser H.H. RNA analysis by MEKC with LIF detection. Electrophoresis 2007, 28(21):3901-3907.
26. + T cell responses during longitudinal study of acute human hepatitis C. Hepatology 2005, 42(1):104-112.
27. Crawford R., Dogdas B., Keough E., Haas R.M., Wepukhulu W., Krotzer S., et al. Analysis of lipid nanoparticles by Cryo-EM for characterizing siRNA delivery vehicles. International Journal of Pharmaceutics 2011, 403(1-2):237-244.
28. Cu Y., Broderick K., Banerjee K., Hickman J., Otten G., Barnett S., et al. Enhanced delivery and potency of self-amplifying mRNA vaccines by electroporation in situ. Vaccines 2013, 1(3):367-383.
29. Cunningham L., Kittikamron K., Lu Y. Preparative-scale purification of RNA using an efficient method which combines gel electrophoresis and column chromatography. Nucleic Acids Research 1996, 24(18):3647-3648.
30. Dai Q., Fong R., Saikia M., Stephenson D., Yu Y.T., Pan T., et al. Identification of recognition residues for ligation-based detection and quantitation of pseudouridine and N6-methyladenosine. Nucleic Acids Research 2007, 35(18):6322-6329.
31. Dasari V., Smith C., Khanna R. Recent advances in designing an effective vaccine to prevent cytomegalovirus-associated clinical diseases. Expert Review of Vaccines 2013, 12(6):661-676.
32. Davis R.H. Large-scale oligoribonucleotide production. Current Opinion in Biotechnology 1995, 6(2):213-217.
33. De Gregorio E., Tritto E., Rappuoli R. Alum adjuvanticity: unraveling a century old mystery. European Journal of Immunology 2008, 38(8):2068-2071.
34. Dean H.J., Haynes J., Schmaljohn C. The role of particle-mediated DNA vaccines in biodefense preparedness. Advanced Drug Delivery Reviews 2005, 57(9):1315-1342.
35. Deering R.P., Kommareddy S., Ulmer J.B., Brito L.A., Geall A.J. Nucleic acid vaccines: prospects for non-viral delivery of mRNA vaccines. Expert Opinion on Drug Delivery 2014, 11(6):885-899.
36. Demana P.H., Fehske C., White K., Rades T., Hook S. Effect of incorporation of the adjuvant Quil A on structure and immune stimulatory capacity of liposomes. Immunology & Cell Biology 2004, 82(5):547-554.
37. Diepolder H.M., Zachoval R., Hoffmann R.M., Wierenga E.A., Santantonio T., Jung M.C., et al. Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection. Lancet 1995, 346(8981):1006-1007.
38. Dolan A., Cunningham C., Hector R.D., Hassan-Walker A.F., Lee L., Addison C., et al. Genetic content of wild-type human cytomegalovirus. Journal of General Virology 2004, 85(Pt 5):1301-1312.
39. Durairaj A., Limbach P.A. Improving CMC-derivatization of pseudouridine in RNA for mass spectrometric detection. Analytica Chimica Acta 2008, 612(2):173-181.
40. Eastman S.J., Siegel C., Tousignant J., Smith A.E., Cheng S.H., Scheule R.K. Biophysical characterization of cationic lipid: DNA complexes. Biochimica et Biophysica Acta 1997, 1325(1):41-62.
41. Ertl H.C. Novel vaccines to human rabies. PLoS Neglected Tropical Diseases 2009, 3(9):e515.
42. Evans J.S., Horton D.L., Easton A.J., Fooks A.R., Banyard A.C. Rabies virus vaccines: is there a need for a pan-lyssavirus vaccine?. Vaccine 2012, 30(52):7447-7454.
43. Evans R.K., Xu Z., Bohannon K.E., Wang B., Bruner M.W., Volkin D.B. Evaluation of degradation pathways for plasmid DNA in pharmaceutical formulations via accelerated stability studies. Journal of Pharmaceutical Sciences 2000, 89(1):76-87.
44. Fasol U., Frost A., Buchert M., Arends J., Fiedler U., Scharr D., et al. Vascular and pharmacokinetic effects of EndoTAG-1 in patients with advanced cancer and liver metastasis. Annals of Oncology 2012, 23(4):1030-1036.
45. Ferreira G.N., Cabral J.M., Prazeres D.M. Development of process flow sheets for the purification of supercoiled plasmids for gene therapy applications. Biotechnology Progress 1999, 15(4):725-731.
46. Fischer L., Minke J., Dufay N., Baudu P., Audonnet J.C. Rabies DNA vaccine in the horse: strategies to improve serological responses. Vaccine 2003, 21(31):4593-4596.
47. Folgori A., Capone S., Ruggeri L., Meola A., Sporeno E., Ercole B.B., et al. A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees. Nature Medicine 2006, 12(2):190-197.
48. Fournillier A., Depla E., Karayiannis P., Vidalin O., Maertens G., Trepo C., et al. Expression of noncovalent hepatitis C virus envelope E1-E2 complexes is not required for the induction of antibodies with neutralizing properties following DNA immunization. Journal of Virology 1999, 73(9):7497-7504.
49. Freund J., Casals J., Hosmer E.P. Sensitization and antibody formation after injection of tubercle bacilli and paraffin oil. Experimental Biology and Medicine 1937, 37(3):509-513.
50. Frey S.E., Harrison C., Pass R.F., Yang E., Boken D., Sekulovich R.E., et al. Effects of antigen dose and immunization regimens on antibody responses to a cytomegalovirus glycoprotein B subunit vaccine. Journal of Infectious Diseases 1999, 180(5):1700-1703.
51. Fuller D.H., Loudon P., Schmaljohn C. Preclinical and clinical progress of particle-mediated DNA vaccines for infectious diseases. Methods 2006, 40(1):86-97.
52. Fuller D.H., Rajakumar P.A., Wilson L.A., Trichel A.M., Fuller J.T., Shipley T., et al. Induction of mucosal protection against primary, heterologous simian immunodeficiency virus by a DNA vaccine. Journal of Virology 2002, 76(7):3309-3317.
53. Garneau N.L., Wilusz J., Wilusz C.J. The highways and byways of mRNA decay. Nature Reviews Molecular Cell Biology 2007, 8(2):113-126.
54. Geall A.J., Mandl C.W., Ulmer J.B. RNA: the new revolution in nucleic acid vaccines. Seminars in Immunology 2013, 25(2):152-159.
55. Geall A.J., Verma A., Otten G.R., Shaw C.A., Hekele A., Banerjee K., et al. Nonviral delivery of self-amplifying RNA vaccines. Proceedings of the National Academy of Sciences of the United States of America 2012, 109(36):14604-14609.
56. Giddam A.K., Zaman M., Skwarczynski M., Toth I. Liposome-based delivery system for vaccine candidates: constructing an effective formulation. Nanomedicine (Lond) 2012, 7(12):1877-1893.
57. Gilbert S.C. Clinical development of modified vaccinia virus ankara vaccines. Vaccine 2013, 31(39):4241-4246.
58. Gingras A.C., Raught B., Sonenberg N. eIF4 initiation factors: effectors of mRNA recruitment to ribosomes and regulators of translation. Annual Review of Biochemistry 1999, 68:913-963.
59. Glover D.J. Artificial viruses: exploiting viral trafficking for therapeutics. Infectious Disorders - Drug Targets 2012, 12(1):68-80.
60. Gothelf A., Gehl J. What you always needed to know about electroporation based DNA vaccines. Human Vaccines & Immunotherapeutics 2012, 8(11):1694-1702.
61. Grakoui A., Shoukry N.H., Woollard D.J., Han J.H., Hanson H.L., Ghrayeb J., et al. HCV persistence and immune evasion in the absence of memory T cell help. Science 2003, 302(5645):659-662.
62. Gratton S.E., Ropp P.A., Pohlhaus P.D., Luft J.C., Madden V.J., Napier M.E., et al. The effect of particle design on cellular internalization pathways. Proceedings of the National Academy of Sciences of the United States of America 2008, 105(33):11613-11618.
63. Gregoriadis G., Bacon A., Caparros-Wanderley W., McCormack B. A role for liposomes in genetic vaccination. Vaccine 2002, 20(Suppl. 5):B1-B9.
64. Gregory A.E., Titball R., Williamson D. Vaccine delivery using nanoparticles. Frontiers in Cellular & Infection Microbiology 2013, 3:13.
65. Guo P.X., Moss B. Interaction and mutual stabilization of the two subunits of vaccinia virus mRNA capping enzyme coexpressed in Escherichia coli. Proceedings of the National Academy of Sciences of the United States of America 1990, 87(11):4023-4027.
66. Gupta P.K., Dahiya S.S., Kumar P., Rai A., Patel C.L., Sonwane A.A., et al. Sindbis virus replicon-based DNA vaccine encoding Rabies virus glycoprotein elicits specific humoral and cellular immune response in dogs. Acta Virologica 2009, 53(2):83-88.
67. Hafez I.M., Maurer N., Cullis P.R. On the mechanism whereby cationic lipids promote intracellular delivery of polynucleic acids. Gene Therapy 2001, 8(15):1188-1196.
68. ® vaccine against H7N9 influenza is immunogenic in mice. Emerging Microbes & Infections 2013, 2(8).
69. Heyes J., Palmer L., Bremner K., MacLachlan I. Cationic lipid saturation influences intracellular delivery of encapsulated nucleic acids. Journal of Controlled Release 2005, 107(2):276-287.
70. Hicks D.J., Fooks A.R., Johnson N. Developments in rabies vaccines. Clinical & Experimental Immunology 2012, 169(3):199-204.
71. Houseley J., Tollervey D. The many pathways of RNA degradation. Cell 2009, 136(4):763-776.
72. Hsu M., Zhang J., Flint M., Logvinoff C., Cheng-Mayer C., Rice C.M., et al. Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles. Proceedings of the National Academy of Sciences of the United States of America 2003, 100(12):7271-7276.
73. Huth S., Hoffmann F., von Gersdorff K., Laner A., Reinhardt D., Rosenecker J., et al. Interaction of polyamine gene vectors with RNA leads to the dissociation of plasmid DNA-carrier complexes. Journal of Gene Medicine 2006, 8(12):1416-1424.
74. Iacobucci I., Ferrarini A., Sazzini M., Giacomelli E., Lonetti A., Xumerle L., et al. Application of the whole-transcriptome shotgun sequencing approach to the study of Philadelphia-positive acute lymphoblastic leukemia. Blood Cancer Journal 2012, 2:e61.
75. Immordino M.L., Dosio F., Cattel L. Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. International Journal of Nanomedicine 2006, 1(3):297-315.
76. Ishii K., Rosa D., Watanabe Y., Katayama T., Harada H., Wyatt C., et al. High titers of antibodies inhibiting the binding of envelope to human cells correlate with natural resolution of chronic hepatitis C. Hepatology 1998, 28(4):1117-1120.
77. Jacobs A.C., Resendiz M.J., Greenberg M.M. Direct strand scission from a nucleobase radical in RNA. Journal of American Chemical Society 2010, 132(11):3668-3669.
78. Jarve A., Muller J., Kim I.H., Rohr K., MacLean C., Fricker G., et al. Surveillance of siRNA integrity by FRET imaging. Nucleic Acids Research 2007, 35(18):e124.
79. Jeffs L.B., Palmer L.R., Ambegia E.G., Giesbrecht C., Ewanick S., MacLachlan I. A scalable, extrusion-free method for efficient liposomal encapsulation of plasmid DNA. Pharmaceutical Research 2005, 22(3):362-372.
80. Johanning F.W., Conry R.M., LoBuglio A.F., Wright M., Sumerel L.A., Pike M.J., et al. A Sindbis virus mRNA polynucleotide vector achieves prolonged and high level heterologous gene expression in vivo. Nucleic Acids Research 1995, 23(9):1495-1501.
81. Johansson D.X., Ljungberg K., Kakoulidou M., Liljestrom P. Intradermal electroporation of naked replicon RNA elicits strong immune responses. PLoS One 2012, 7(1):e29732.
82. Johnson J.A., Barouch D.H., Baden L.R. Nonreplicating vectors in HIV vaccines. Current Opinion in HIV and AIDS 2013, 8(5):412-420.
83. Jones K.L., Drane D., Gowans E.J. Long-term storage of DNA-free RNA for use in vaccine studies. Biotechniques 2007, 43(5):675-681.
84. Jose J., Snyder J.E., Kuhn R.J. A structural and functional perspective of alphavirus replication and assembly. Future Microbiology 2009, 4(7):837-856.
85. Kallen K.J., Heidenreich R., Schnee M., Petsch B., Schlake T., Thess A., et al. A novel, disruptive vaccination technology: self-adjuvanted RNActive vaccines. Human Vaccines & Immunotherapeutics 2013, 9(10).
86. Kallen K.J., Thess A. A development that may evolve into a revolution in medicine: mRNA as the basis for novel, nucleotide-based vaccines and drugs. Therapeutic Advances in Vaccines 2014, 2(1):10-31.
87. Kariko K., Muramatsu H., Ludwig J., Weissman D. Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA. Nucleic Acids Research 2011, 39(21):e142.
88. Karmali P.P., Chaudhuri A. Cationic liposomes as non-viral carriers of gene medicines: resolved issues, open questions, and future promises. Medicinal Research Reviews 2007, 27(5):696-722.
89. Kellner S., Burhenne J., Helm M. Detection of RNA modifications. RNA Biology 2010, 7(2):237-247.
90. Kenneson A., Cannon M.J. Review and meta-analysis of the epidemiology ofcongenital cytomegalovirus (CMV) infection. Reviews in Medical Virology 2007, 17(4):253-276.
91. Kichaev G., Mendoza J.M., Amante D., Smith T.R., McCoy J.R., Sardesai N.Y., et al. Electroporation mediated DNA vaccination directly to a mucosal surface results in improved immune responses. Human Vaccines & Immunotherapeutics 2013, 9(10):2041-2048.
92. Kielian M., Rey F.A. Virus membrane-fusion proteins: more than one way to make a hairpin. Nature Reviews Microbiology 2006, 4(1):67-76.
93. Knobel D.L., Cleaveland S., Coleman P.G., Fevre E.M., Meltzer M.I., Miranda M.E., et al. Re-evaluating the burden of rabies in Africa and Asia. Bulletin of the World Health Organization 2005, 83(5):360-368.
94. Kofler R.M., Aberle J.H., Aberle S.W., Allison S.L., Heinz F.X., Mandl C.W. Mimicking live flavivirus immunization with a noninfectious RNA vaccine. Proceedings of the National Academy of Sciences of the United States of America 2004, 101(7):1951-1956.
95. Koltover I., Salditt T., Radler J.O., Safinya C.R. An inverted hexagonal phase of cationic liposome-DNA complexes related to DNA release and delivery. Science 1998, 281(5373):78-81.
96. Kovalsky O.I., Panyutin I.G., Budowsky E.I. Sequence-specificity of the alkali-sensitive lesions induced in DNA by high-intensity ultraviolet laser radiation. Photochemistry and Photobiology 1990, 52(3):509-517.
97. Krause P.R., Bialek S.R., Boppana S.B., Griffiths P.D., Laughlin C.A., Ljungman P., et al. Priorities for CMV vaccine development. Vaccine 2013, 32(1):4-10.
98. Krieg P.A., Melton D.A. Functional messenger RNAs are produced by SP6 in vitro transcription of cloned cDNAs. Nucleic Acids Research 1984, 12(18):7057-7070.
99. Kuhn R.J. Togaviridae: the viruses and their replication. Fields virology 2007, Vol. 1:1001-1022. Lippincott Williams & Wilkins, Philadelphia, Baltimore, New York, London, Buenos Aires, Hong Kong, Sydney, Tokyo. 5th ed.
100. Kulkarni V., Rosati M., Bear J., Pilkington G.R., Jalah R., Bergamaschi C., et al. Comparison of intradermal and intramuscular delivery followed by in vivo electroporation of SIV Env DNA in macaques. Human Vaccines & Immunotherapeutics 2013, 9(10):2081-2094.
101. Kuo K.C., Smith C.E., Shi Z.X., Agris P.F., Gehrke C.W. Quantitative measurement of mRNA cap 0 and cap 1 structures by high-performance liquid chromatography. Journal of Chromatography 1986, 378(2):361-374.
102. Kupfer P.A., Leumann C.J. The chemical stability of abasic RNA compared to abasic DNA. Nucleic Acids Research 2007, 35(1):58-68.
103. Kutzler M.A., Weiner D.B. DNA vaccines: ready for prime time?. Nature Reviews Genetics 2008, 9(10):776-788.
104. La Rosa C., Longmate J., Lacey S.F., Kaltcheva T., Sharan R., Marsano D., et al. Clinical evaluation of safety and immunogenicity of PADRE-cytomegalovirus (CMV) and tetanus-CMV fusion peptide vaccines with or without PF03512676 adjuvant. Journal of Infectious Diseases 2012, 205(8):1294-1304.
105. Lechner F., Wong D.K., Dunbar P.R., Chapman R., Chung R.T., Dohrenwend P., et al. Analysis of successful immune responses in persons infected with hepatitis C virus. Journal of Experimental Medicine 2000, 191(9):1499-1512.
106. Leitner W.W., Ying H., Restifo N.P. DNA and RNA-based vaccines: principles, progress and prospects. Vaccine 1999, 18(9-10):765-777.
107. Leung A.K., Hafez I.M., Baoukina S., Belliveau N.M., Zhigaltsev I.V., Afshinmanesh E., et al. Lipid nanoparticles containing siRNA synthesized by microfluidic mixing exhibit an electron-dense nanostructured core. Journal of Physical Chemistry C: Nanomater Interfaces 2012, 116(34):18440-18450.
108. Li S.D., Huang L. Gene therapy progress and prospects: non-viral gene therapy by systemic delivery. Gene Therapy 2006, 13(18):1313-1319.
109. Lilja A.E., Mason P.W. The next generation recombinant human cytomegalovirus vaccine candidates-beyond gB. Vaccine 2012, 30(49):6980-6990.
110. Liljestrom P., Garoff H. A new generation of animal cell expression vectors based on the Semliki Forest virus replicon. Biotechnology (N Y) 1991, 9(12):1356-1361.
111. Lin Y., Kwon T., Polo J., Zhu Y.F., Coates S., Crawford K., et al. Induction ofbroad CD4+ and CD8+ T-cell responses and cross-neutralizing antibodies against hepatitis C virus by vaccination with Th1-adjuvanted polypeptides followed by defective alphaviral particles expressing envelope glycoproteins gpE1 and gpE2 and nonstructural proteins 3, 4, and 5. Journal of Virology 2008, 82(5):7492-7503.
112. Lipkin D., Talbert P.T., Cohn M. The mechanism of the alkaline hydrolysis of ribonucleic acids. Journal of American Chemical Society 1954, 76(11):2871-2872.
113. Liu M.A. DNA vaccines: an historical perspective and view to the future. Immunological Reviews 2011, 239(1):62-84.
114. Liu F., Huang L. Development of non-viral vectors for systemic gene delivery. Journal of Controlled Release 2002, 78(1-3):259-266.
115. Lodmell D.L., Parnell M.J., Bailey J.R., Ewalt L.C., Hanlon C.A. Rabies DNA vaccination of non-human primates: post-exposure studies using gene gun methodology that accelerates induction of neutralizing antibody and enhances neutralizing antibody titers. Vaccine 2002, 20(17-18):2221-2228.
116. Lodmell D.L., Ray N.B., Ewalt L.C. Gene gun particle-mediated vaccination with plasmid DNA confers protective immunity against rabies virus infection. Vaccine 1998, 16(2-3):115-118.
117. Lodmell D.L., Ray N.B., Parnell M.J., Ewalt L.C., Hanlon C.A., Shaddock J.H., et al. DNA immunization protects nonhuman primates against rabies virus. Nature Medicine 1998, 4(8):949-952.
118. Loomis R.J., Lilja A.E., Monroe J., Balabanis K.A., Brito L.A., Palladino G., et al. Vectored co-delivery of human cytomegalovirus gH and gL proteins elicits potent complement-independent neutralizing antibodies. Vaccine 2013, 31(6):919-926.
119. Lukavsky P.J., Puglisi J.D. Large-scale preparation and purification of polyacrylamide-free RNA oligonucleotides. RNA 2004, 10(5):889-893.
120. Lundstrom K. Alphavirus vectors: applications for DNA vaccine production and gene expression. Intervirology 2000, 43(4-6):247-257.
121. Lu C., Stewart D.J., Lee J.J., Ji L., Ramesh R., Jayachandran G., et al. Phase I clinical trial of systemically administered TUSC2(FUS1)-nanoparticles mediating functional gene transfer in humans. PLoS One 2012, 7(4):e34833.
122. Mandl C.W., Aberle J.H., Aberle S.W., Holzmann H., Allison S.L., Heinz F.X. In vitro-synthesized infectious RNA as an attenuated live vaccine in a flavivirus model. Nature Medicine 1998, 4(12):1438-1440.
123. Manthorpe M., Hobart P., Hermanson G., Ferrari M., Geall A., Goff B., et al. Plasmid vaccines and therapeutics: from design to applications. Advances in Biochemical Engineering/Biotechnology 2005, 99:41-92.
124. Mao X., Shuman S. Intrinsic RNA (guanine-7) methyltransferase activity of the vaccinia virus capping enzyme D1 subunit is stimulated by the D12 subunit. Identification of amino acid residues in the D1 protein required for subunit association and methyl group transfer. Journal of Biological Chemistry 1994, 269(39):24472-24479.
125. Marcotrigiano J., Gingras A.C., Sonenberg N., Burley S.K. Cocrystal structure of the messenger RNA 5' cap-binding protein (eIF4E) bound to 7-methyl-GDP. Cell 1997, 89(6):951-961.
126. Margalith M., Vilalta A. Sustained protective rabies neutralizing antibody titers after administration of cationic lipid-formulated pDNA vaccine. Genetic Vaccines and Therapy 2006, 4:2.
127. Martinon F., Krishnan S., Lenzen G., Magne R., Gomard E., Guillet J.G., et al. Induction of virus-specific cytotoxic T lymphocytes in vivo by liposome-entrapped mRNA. European Journal of Immunology 1993, 23(7):1719-1722.
128. Maurer N., Wong K.F., Stark H., Louie L., McIntosh D., Wong T., et al. Spontaneous entrapment of polynucleotides upon electrostatic interaction with ethanol-destabilized cationic liposomes. Biophysical Journal 2001, 80(5):2310-2326.
129. McVoy M.A. Cytomegalovirus vaccines. Clinical Infectious Diseases 2013, 57(Suppl. 4):S196-S199.
130. Melton D.A., Krieg P.A., Rebagliati M.R., Maniatis T., Zinn K., Green M.R. Efficient in vitro synthesis of biologically active RNA and RNA hybridization probes from plasmids containing a bacteriophage SP6 promoter. Nucleic Acids Research 1984, 12(18):7035-7056.
131. Meunier J.C., Russell R.S., Goossens V., Priem S., Walter H., Depla E., et al. Isolation and characterization of broadly neutralizing human monoclonal antibodies to the e1 glycoprotein of hepatitis C virus. Journal of Virology 2008, 82(2):966-973.
132. Mikkola S., Kosonen, Lonnberg H. Cleavage and isomerization of RNA phosphodiester bonds: nucleoside Phosphotriesters and chimeric Ribo/2'-O-Methylribo oligonucleotides as tools for mechanistic studies. Current Organic Chemistry 2002, 6(6):523-538.
133. Milligan J.F., Groebe D.R., Witherell G.W., Uhlenbeck O.C. Oligoribonucleotide synthesis using T7 RNA polymerase and synthetic DNA templates. Nucleic Acids Research 1987, 15(21):8783-8798.
134. Moon S.L., Wilusz J. In vitro transcription of modified RNAs. Methods in Molecular Biology 2012, 941:171-180.
135. Morrissey D.V., Lockridge J.A., Shaw L., Blanchard K., Jensen K., Breen W., et al. Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nature Biotechnology 2005, 23(8):1002-1007.
136. Mosca F., Tritto E., Muzzi A., Monaci E., Bagnoli F., Iavarone C., et al. Molecular and cellular signatures of human vaccine adjuvants. Proceedings of the National Academy of Sciences of the United States of America 2008, 105(30):10501-10506.
137. Motorin Y., Muller S., Behm-Ansmant I., Branlant C. Identification of modified residues in RNAs by reverse transcription-based methods. Methods in Enzymology 2007, 425:21-53.
138. Muller J.G., Hickerson R.P., Perez R.J., Burrows C.J. DNA damage from sulfite autoxidation catalyzed by a Nickel(II) peptide. Journal of American Chemical Society 1997, 119(7):1501-1506.
139. O'Hagan D.T., Ott G.S., De Gregorio E., Seubert A. The mechanism of action of MF59-an innately attractive adjuvant formulation. Vaccine 2012, 30(29):4341-4348.
140. O'Hagan D.T., Ott G.S., Nest G.V., Rappuoli R., Giudice G.D. The history of MF59((R)) adjuvant: a phoenix that arose from the ashes. Expert Review of Vaccines 2013, 12(1):13-30.
141. Oivanen M., Kuusela S., Lonnberg H. Kinetics and mechanisms for the cleavage and isomerization of the phosphodiester bonds of RNA by bronsted acids and bases. Chemical Reviews 1998, 98(3):961-990.
142. Ott G., Singh M., Kazzaz J., Briones M., Soenawan E., Ugozzoli M., et al. A cationic sub-micron emulsion (MF59/DOTAP) is an effective delivery system for DNA vaccines. Journal of Controlled Release 2002, 79(1-3):1-5.
143. Pascolo S. Messenger RNA-based vaccines. Expert Opinion on Biological Therapy 2004, 4(8):1285-1294.
144. Pascolo S. Vaccination with messenger RNA (mRNA). Handbook of Experimental Pharmacology 2008, 183:221-235.
145. Pass R.F., Duliege A.M., Boppana S., Sekulovich R., Percell S., Britt W., et al. A subunit cytomegalovirus vaccine based on recombinant envelope glycoprotein B and a new adjuvant. Journal of Infectious Diseases 1999, 180(4):970-975.
146. Payne L.G., Fuller D.H., Haynes J.R. Particle-mediated DNA vaccination of mice, monkeys and men: looking beyond the dogma. Current Opinion in Molecular Therapeutics 2002, 4(5):459-466.
147. Peng Z.H., Sharma V., Singleton S.F., Gershon P.D. Synthesis and application of a chain-terminating dinucleotide mRNA cap analog. Organic Letters 2002, 4(2):161-164.
148. Perrie Y., Frederik P.M., Gregoriadis G. Liposome-mediated DNA vaccination: the effect of vesicle composition. Vaccine 2001, 19(23-24):3301-3310.
149. Petsch B., Schnee M., Vogel A.B., Lange E., Hoffmann B., Voss D., et al. Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection. Nature Biotechnology 2012, 30(12):1210-1216.
150. Pickering B.M., Willis A.E. The implications of structured 5' untranslated regions on translation and disease. Seminars in Cell & Developmental Biology 2005, 16(1):39-47.
151. Piggott J.M., Sheahan B.J., Soden D.M., O'Sullivan G.C., Atkins G.J. Electroporation of RNA stimulates immunity to an encoded reporter gene in mice. Molecular Medicine Reports 2009, 2(5):753-756.
152. Pileri P., Uematsu Y., Campagnoli S., Galli G., Falugi F., Petracca R., et al. Binding of hepatitis C virus to CD81. Science 1998, 282(5390):938-941.
153. Pushko P., Parker M., Ludwig G.V., Davis N.L., Johnston R.E., Smith J.F. Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo. Virology 1997, 239(2):389-401.
154. Qiu P., Ziegelhoffer P., Sun J., Yang N.S. Gene gun delivery of mRNA in situ results in efficient transgene expression and genetic immunization. Gene Therapy 1996, 3(3):262-268.
155. Ray N.B., Ewalt L.C., Lodmell D.L. Nanogram quantities of plasmid DNA encoding the rabies virus glycoprotein protect mice against lethal rabies virus infection. Vaccine 1997, 15(8):892-895.
156. Rayner J.O., Dryga S.A., Kamrud K.I. Alphavirus vectors and vaccination. Reviews in Medical Virology 2002, 12(5):279-296.
157. Rejman J., Bragonzi A., Conese M. Role of clathrin- and caveolae-mediated endocytosis in gene transfer mediated by lipo- and polyplexes. Molecular Therapy 2005, 12(3):468-474.
158. Rochard A., Scherman D., Bigey P. Genetic immunization with plasmid DNA mediated by electrotransfer. Human Gene Therapy 2011, 22(7):789-798.
159. Ross J. mRNA stability in mammalian cells. Microbiological Reviews 1995, 59(3):423-450.
160. Ruthardt N., Lamb D.C., Brauchle C. Single-particle tracking as a quantitative microscopy-based approach to unravel cell entry mechanisms of viruses and pharmaceutical nanoparticles. Molecular Therapy 2011, 19(7):1199-1211.
161. Saade F., Petrovsky N. Technologies for enhanced efficacy of DNA vaccines. Expert Review of Vaccines 2012, 11(2):189-209.
162. Sachsenmaier N., Handl S., Debeljak F., Waldsich C. Mapping RNA structure in vitro using nucleobase-specific probes. Methods in Molecular Biology 2014, 1086:79-94.
163. Saikia M., Fu Y., Pavon-Eternod M., He C., Pan T. Genome-wide analysis of N1-methyl-adenosine modification in human tRNAs. RNA 2010, 16(7):1317-1327.
164. Saito I., Takayama M., Sugiyama H., Nakatani K., Tsuchida A., Yamamoto M. Photoinduced DNA cleavage via electron Transfer: demonstration that guanine residues located 5' to guanine are the most electron-donating sites. Journal of American Chemical Society 1995, 117(23):6406-6407.
165. Sardesai N.Y., Weiner D.B. Electroporation delivery of DNA vaccines: prospects for success. Current Opinion in Immunology 2011, 23(3):421-429.
166. Saxena S., Sonwane A.A., Dahiya S.S., Patel C.L., Saini M., Rai A., et al. Induction of immune responses and protection in mice against rabies using a self-replicating RNA vaccine encoding rabies virus glycoprotein. Veterinary Microbiology 2009, 136(1-2):36-44.
167. Saxena M., Van T.T., Baird F.J., Coloe P.J., Smooker P.M. Pre-existing immunity against vaccine vectors-friend or foe?. Microbiology 2013, 159(Pt 1):1-11.
168. Schlake T., Thess A., Fotin-Mleczek M., Kallen K.J. Developing mRNA-vaccine technologies. RNA Biology 2012, 9(11):1319-1330.
169. Schleiss M.R., Heineman T.C. Progress toward an elusive goal: current status of cytomegalovirus vaccines. Expert Review of Vaccines 2005, 4(3):381-406.
170. Schlesinger S. Alphavirus vectors: development and potential therapeutic applications. Expert Opinion on Biological Therapy 2001, 1(2):177-191.
171. Semple S.C., Akinc A., Chen J., Sandhu A.P., Mui B.L., Cho C.K., et al. Rational design of cationic lipids for siRNA delivery. Nat Biotechnol 2010, 28(2):172-176.
172. Semple S.C., Klimuk S.K., Harasym T.O., Dos Santos N., Ansell S.M., Wong K.F., et al. Efficient encapsulation of antisense oligonucleotides in lipid vesicles using ionizable aminolipids: formation of novel small multilamellar vesicle structures. Biochimica et Biophysica Acta 2001, 1510(1-2):152-166.
173. Setlow R.B., Carrier W.L., Bollum F.J. Pyrimidine dimers in UV-irradiated poly dI:dC. Proceedings of the National Academy of Sciences 1965, 53(5):1111-1118.
174. Seubert A., Monaci E., Pizza M., O'Hagan D.T., Wack A. The adjuvants aluminum hydroxide and MF59 induce monocyte and granulocyte chemoattractants and enhance monocyte differentiation toward dendritic cells. Journal of Immunology 2008, 180(8):5402-5412.
175. Shatkin A.J. Capping of eucaryotic mRNAs. Cell 1976, 9(4 Pt 2):645-653.
176. Shin G., Yost S.A., Miller M.T., Elrod E.J., Grakoui A., Marcotrigiano J. Structural and functional insights into alphavirus polyprotein processing and pathogenesis. Proceedings of the National Academy of Sciences of the United States of America 2012, 109(41):16534-16539.
177. Smerdou C., Liljestrom P. Non-viral amplification systems for gene transfer: vectors based on alphaviruses. Current Opinion in Molecular Therapy 1999, 1(2):244-251.
178. Stadler J., Lemmens R., Nyhammar T. Plasmid DNA purification. Journal of Gene Medicine 2004, 6(Suppl. 1):S54-S66.
179. Staras S.A., Dollard S.C., Radford K.W., Flanders W.D., Pass R.F., Cannon M.J. Seroprevalence of cytomegalovirus infection in the United States, 1988-1994. Clinical Infectious Diseases 2006, 43(9):1143-1151.
180. Stern-Ginossar N., Weisburd B., Michalski A., Le V.T., Hein M.Y., Huang S.X., et al. Decoding human cytomegalovirus. Science 2012, 338(6110):1088-1093.
181. Tacket C.O., Roy M.J., Widera G., Swain W.F., Broome S., Edelman R. Phase 1 safety and immune response studies of a DNA vaccine encoding hepatitis B surface antigen delivered by a gene delivery device. Vaccine 1999, 17(22):2826-2829.
182. Tam Y.Y., Chen S., Cullis P.R. Advances in lipid nanoparticles for siRNA delivery. Pharmaceutics 2013, 5(3):498-507.
183. Tamm C., Shapiro H.S., Lipshitz R., Chargaff E. Distribution density of nucleotides within a desoxyribonucleic acid chain. Journal of Biological Chemistry 1953, 203(2):673-688.
184. Uematsu Y., Vajdy M., Lian Y., Perri S., Greer C.E., Legg H.S., et al. Lack of interference with immunogenicity of a chimeric alphavirus replicon particle-based influenza vaccine by preexisting antivector immunity. Clinical and Vaccine Immunology 2012, 19(7):991-998.
185. Vajdy M., Srivastava I., Polo J., Donnelly J., O'Hagan D., Singh M. Mucosal adjuvants and delivery systems for protein-, DNA- and RNA-based vaccines. Immunology & Cell Biology 2004, 82(6):617-627.
186. Vancini R., Wang G., Ferreira D., Hernandez R., Brown D.T. Alphavirus genome delivery occurs directly at the plasma membrane in a time- and temperature-dependent process. Journal of Virology 2013, 87(8):4352-4359.
187. Vono M., Taccone M., Caccin P., Gallotta M., Donvito G., Falzoni S., et al. The adjuvant MF59 induces ATP release from muscle that potentiates response to vaccination. Proceedings of the National Academy of Sciences of the United States of America 2013, 110(52):21095-21100.
188. Wang D., Fu T.M. Progress on human cytomegalovirus vaccines for prevention of congenital infection and disease. Current Opinion in Virology 2014, 6C:13-23.
189. Wang Z., Gerstein M., Snyder M. RNA-Seq: a revolutionary tool for transcriptomics. Nature Reviews Genetics 2009, 10(1):57-63.
190. Wang Y., Su H.H., Yang Y., Hu Y., Zhang L., Blancafort P., et al. Systemic delivery of modified mRNA encoding herpes simplex virus 1 thymidine kinase for targeted cancer gene therapy. Molecular Therapy 2013, 21(2):358-367.
191. Warrell M.J. Current rabies vaccines and prophylaxis schedules: preventing rabies before and after exposure. Travel Medicine and Infectious Disease 2012, 10(1):1-15.
192. Weaver S.C., Ferro C., Barrera R., Boshell J., Navarro J.C. Venezuelan equine encephalitis. Annual Review of Entomology 2004, 49:141-174.
193. Welch R.J., Anderson B.L., Litwin C.M. An evaluation of two commercially available ELISAs and one in-house reference laboratory ELISA for the determination of human anti-rabies virus antibodies. Journal of Medical Microbiology 2009, 58(Pt 6):806-810.
194. Wen Y., Monroe J., Linton C., Archer J., Beard C.W., Barnett S.W., et al. Human cytomegalovirus gH/gL/UL128/UL130/UL131A complex elicits potently neutralizing antibodies in mice. Vaccine 2014, 32(30):3796-3804.
195. Wloch M.K., Smith L.R., Boutsaboualoy S., Reyes L., Han C., Kehler J., et al. Safety and immunogenicity of a bivalent cytomegalovirus DNA vaccine in healthy adult subjects. Journal of Infectious Diseases 2008, 197(12):1634-1642.
196. Wolff J.A., Malone R.W., Williams P., Chong W., Acsadi G., Jani A., et al. Direct gene transfer into mouse muscle in vivo. Science 1990, 247(4949 Pt 1):1465-1468.
197. Woodle M.C., Scaria P. Cationic liposomes and nucleic acids. Current Opinion in Colloid & Interface Science 2001, 6(1):78-84.
198. Wrammert J., Miller J., Akondy R., Ahmed R. Human immune memory to yellow fever and smallpox vaccination. Journal of Clinical Immunology 2009, 29(2):151-157.
199. Wyatt J.R., Chastain M., Puglisi J.D. Synthesis and purification of large amounts of RNA oligonucleotides. Biotechniques 1991, 11(6):764-769.
200. Xu J., Luft J.C., Yi X., Tian S., Owens G., Wang J., et al. RNA replicon delivery via lipid-complexed PRINT protein particles. Molecular Pharmaceutics 2013, 10(9):3366-3374.
201. Xu Y., Szoka F.C. Mechanism of DNA release from cationic liposome/DNA complexes used in cell transfection. Biochemistry 1996, 35(18):5616-5623.
202. Xu J., Wang J., Luft J.C., Tian S., Owens G., Pandya A.A., et al. Rendering protein-based particles transiently insoluble for therapeutic applications. Journal of American Chemical Society 2012, 134(21):8774-8777.
203. Zeisel M.B., Felmlee D.J., Baumert T.F. Hepatitis C virus entry. Current Topics in Microbiology and Immunology 2013, 369:87-112.
204. Zhao X., Yu Y.T. Detection and quantitation of RNA base modifications. RNA 2004, 10(6):996-1002.
205. Zhou X., Berglund P., Rhodes G., Parker S.E., Jondal M., Liljestrom P. Self-replicating Semliki Forest virus RNA as recombinant vaccine. Vaccine 1994, 12(16):1510-1514.
206. Zimmer G. RNA replicons - a new approach for influenza virus immunoprophylaxis. Viruses 2010, 2(2):413-434.
207. Zimmermann T.S., Lee A.C., Akinc A., Bramlage B., Bumcrot D., Fedoruk M.N., et al. RNAi-mediated gene silencing in non-human primates. Nature 2006, 441(7089):111-114.